RBC Capital Starts Insmed (INSM) at Outperform

RBC Capital analyst Leonid Timashev initiates coverage on Insmed (NASDAQ: INSM) with a Outperform rating and a price target of $100.00.

The analyst comments "We are initiating with an Outperform rating and $100 price target on INSM. Based on extensive KOL diligence, we believe the brensocatib launch is likely to be among the strongest launches in 2025 driven by significant patient and physician demand on the backdrop of a disease with no effective treatment options; we expect launch momentum to carry forward to a $8.2B peak sales opportunity for the drug in bronchiectasis. We also see potential upside in other indications, and Arikayce and TPIP help round out the pipeline's multi-$B value. While shares have continued to do well in the face of pressure on the sector, we still see additional value to be unlocked in the second half of the year, and we would be buyers."

For an analyst ratings summary and ratings history on Insmed click here. For more ratings news on Insmed click here.

Shares of Insmed closed at $81.06 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Greenway Technologies board member Raymond Wright resigns
• SpaceX files for 555.56M share IPO at $135/sh